Food and Drug Administration has given a green signal to a new drug Prolia that will enhance bone strength and avoid fractures in postmenopausal women with osteoporosis.

Women suffering fracture risks generally include those who have already suffered osteoporosis-related fracture or who have suffered failed results in the osteoporosis treatments.

National Institutes of Health shared that nearly half of the women aged above 50 years are at high risk of osteoporosis-related fracture in life.

Prolia is the first drug for osteoporosis which functions by blocking a type of cell that dissolves the bones. Prolia is supposed to be injected by the doctor once in six months. It is also available in the form of pills

"It's a very potent agent and it is pretty clear that the reduction in fracture risk is quite robust," said Dr. Ethel Siris, M. D., the Director of the Osteoporosis Center at Columbia University Medical Center in New York.

Siris was one of the researchers in the study. The team examined as many as 8,000 postmenopausal women with osteoporosis.

The study, which lasted nearly 3 months, was funded by Amgen, the leading drug maker. Prior to the approval of Prolia, two bisphosphonate medications, Reclast and Boniva, were being used by the doctors for osteoporosis patients.